Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Kotoula, Vassiliki ^a   Krikelis, Dimitrios ^a   Karavasilis, Vasilios ^a   Koletsa, Triantafillia ^a   Eleftheraki, Anastasia G ^b   Televantou, Despina ^a   Christodoulou, Christos ^c   Dimoudis, Stefanos ^a   Korantzis, Ippokratis ^a   Pectasides, Dimitrios ^d   Syrigos, Konstantinos N ^e   Kosmidis, Paris A ^f   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c METROPOLITAN HOSPITAL   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e SOTIRIA GENERAL HOSPITAL   (Greece)

^f HYGEIA HOSPITAL   (Greece)

Author keywords

ERCC1; FFPE; mRNA; Normal lung; NSCLC; Predictive; TYMS

Indexed keywords

MESSENGER RNA; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; ENZYME ACTIVITY; ERCC1 GENE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RRM1 GENE; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; TYMS GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; SURVIVAL ANALYSIS; TAXOIDS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84864512270     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-342     Document Type: Article

References (51)

1. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26(28):4617-4625. 2653127, 18678835.
2. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992, 84(19):1512-1517. 10.1093/jnci/84.19.1512, 1433335.
3. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8(7):2286-2291.
4. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006, 17(12):1818-1825. 10.1093/annonc/mdl300, 16980606.
5. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung cancer (Amsterdam, Netherlands) 2010, 70(1):63-70.
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991. 10.1056/NEJMoa060570, 16957145.
7. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27(34):5808-5815. 10.1200/JCO.2009.21.9766, 2793001, 19884554.
8. Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010, 21(9):1817-1824. 10.1093/annonc/mdq053, 20332140.
9. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009, 4(5):e5133. 10.1371/journal.pone.0005133, 2673583, 19415121.
10. Rosell R, Felip E. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol 2001, 28(4 Suppl 14):37-44.
11. Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004, 10(12 Pt 2):4215s-4219s.
12. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63(19):6221-6228.
13. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8:97. 10.1186/1471-2407-8-97, 2394535, 18402708.
14. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007, 2(11):e1129. 10.1371/journal.pone.0001129, 2042516, 17987116.
15. Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Benlloch S, Viteri S, et al. mRNA expression levels and genetic status of genes involved in the EGFR and NF-kappaB pathways in metastatic non-small-cell lung cancer patients. J Transl Med 2011, 9:163. 10.1186/1479-5876-9-163, 3203857, 21951562.
16. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22(10):1878-1885. 10.1200/JCO.2004.12.002, 15143080.
17. Adjei AA. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung cancer (Amsterdam, Netherlands) 2001, 34(Suppl 4):S103-105.
18. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung cancer (Amsterdam, Netherlands) 2011, 74(1):132-138.
19. Takizawa M, Kawakami K, Obata T, Matsumoto I, Ohta Y, Oda M, Sasaki T, Watanabe G. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep 2006, 15(6):1533-1539.
20. Ceppi P, Rapa I, Lo Iacono M, Righi L, Giorcelli J, Pautasso M, Bille A, Ardissone F, Papotti M, Scagliotti GV. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. International journal of cancer 2012, 130(8):1777-1786.
21. Grimminger PP, Schneider PM, Metzger R, Vallbohmer D, Holscher AH, Danenberg PV, Brabender J. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clinical lung cancer 2010, 11(5):328-334. 10.3816/CLC.2010.n.041, 20837458.
22. Nakagawa T, Otake Y, Yanagihara K, Miyahara R, Ishikawa S, Fukushima M, Wada H, Tanaka F. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) 2004, 43(2):145-149.
23. Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K, Hanagiri T. TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung cancer (Amsterdam, Netherlands) 2011, 72(3):360-364.
24. Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008, 112(12):2765-2773. 10.1002/cncr.23491, 18442042.
25. Allingham-Hawkins D, Lea A, Levine S. ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer. PLoS currents 2010, 2:RRN1202. 2998231, 21152077.
26. Andrews J, Yeh P, Pao W, Horn L. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J 2011, 17(2):104-113. 10.1097/PPO.0b013e318213f3cf, 21427554.
27. Hubner RA, Riley RD, Billingham LJ, Popat S. Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations. PLoS One 2011, 6(10):e25164. 10.1371/journal.pone.0025164, 3194810, 22022380.
28. Rothschild SI, Gautschi O, Lara PN, Mack PC, Gandara DR. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol 2011, 23(2):150-157. 10.1097/CCO.0b013e328341ee38, 21119513.
29. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010, 102(3):152-160. 10.1093/jnci/djp477, 2911042, 20075367.
30. Roth JA, Carlson JJ. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clinical lung cancer 2011, 12(6):393-401. 10.1016/j.cllc.2011.04.005, 21723790.
31. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007, 18(6):1043-1050. 10.1093/annonc/mdm072, 17355950.
32. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 2009, 4(10):1212-1220. 10.1097/JTO.0b013e3181b44321, 19687761.
33. Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH. Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thorac Oncol 2009, 4(11):1307-1312. 10.1097/JTO.0b013e3181b9f236, 19745766.
34. Lee MN, Tseng RC, Hsu HS, Chen JY, Tzao C, Ho WL, Wang YC. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007, 13(3):832-838. 10.1158/1078-0432.CCR-05-2694, 17289874.
35. Saviozzi S, Ceppi P, Novello S, Ghio P, Lo Iacono M, Borasio P, Cambieri A, Volante M, Papotti M, Calogero RA, et al. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res 2009, 69(8):3390-3396. 10.1158/0008-5472.CAN-08-2981, 19351853.
36. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127(3):978-983. 10.1378/chest.127.3.978, 15764785.
37. Steiling K, Ryan J, Brody JS, Spira A. The field of tissue injury in the lung and airway. Cancer prevention research (Philadelphia, Pa 2008, 1(6):396-403.
38. Zhang F, Wang ZM, Liu HY, Bai Y, Wei S, Li Y, Wang M, Chen J, Zhou QH. Application of RT-PCR in formalin-fixed and paraffin-embedded lung cancer tissues. Acta pharmacologica Sinica 2011, 31(1):111-117.
39. Sanchez-Navarro I, Gamez-Pozo A, Gonzalez-Baron M, Pinto-Marin A, Hardisson D, Lopez R, Madero R, Cejas P, Mendiola M, Espinosa E, et al. Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. BioTechniques 2010, 48(5):389-397. 10.2144/000113388, 20569212.
40. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M, Scagliotti GV. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107(7):1589-1596. 10.1002/cncr.22208, 16955506.
41. Tanaka F, Wada H, Fukui Y, Fukushima M. Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 2011, 22(8):1791-1797. 10.1093/annonc/mdq730, 21321092.
42. Sun Y, Li T, Ma K, Tian Z, Zhu Y, Chen F, Hu G. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Cancer Invest 2009, 27(9):891-897. 10.3109/07357900902744536, 19832035.
43. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Seminars in respiratory and critical care medicine 2011, 32(1):22-31. 10.1055/s-0031-1272866, 21500121.
44. Choi CM, Yang SC, Jo HJ, Song SY, Jeon YJ, Jang TW, Kim DJ, Jang SH, Yang SH, Kim YD, et al. Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. Ann Oncol 2012, 23(8):2088-2093. 10.1093/annonc/mdr606, 22317771.
45. Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol 2012, PMID: 22269178.
46. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Ann Oncol 2010, 21(12):2324-2332. 10.1093/annonc/mdq204, 20497965.
47. McCord JM, Edeas MA. SOD, oxidative stress and human pathologies: a brief history and a future vision. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2005, 59(4):139-142.
48. Kohli E, Han HY, Zeman AD, Vinogradov SV. Formulations of biodegradable Nanogel carriers with 5'-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. J Control Release 2007, 121(1-2):19-27. 2000331, 17509713.
49. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012, 9(3):144-155. 10.1038/nrclinonc.2012.3, 22330686.
50. Galvani E, Peters GJ, Giovannetti E. Thymidylate synthase inhibitors for non-small cell lung cancer. Expert opinion on investigational drugs 2011, 20(10):1343-1356. 10.1517/13543784.2011.617742, 21905922.
51. Scagliotti GV, Selvaggi G. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. Clinical lung cancer 2008, 9(Suppl 3):S122-128.